Alto Neuroscience investors may be eligible for legal action

Faruqi & Faruqi LLP is investigating potential claims against Alto Neuroscience, Inc. regarding its initial public offering and subsequent stock performance. Investors who purchased Alto stock between February 2, 2024, and October 22, 2024, may be eligible for legal action. Those who suffered losses are encouraged to contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) for further information.

Alto Neuroscience, Inc. (ANRO) Faces Class Action Lawsuit Over Alleged Securities Fraud

A class action lawsuit has been filed against Alto Neuroscience, Inc. (NYSE: ANRO) and certain officers, alleging securities fraud during the company's initial public offering (IPO) and subsequent stock performance. The lawsuit, filed in the United States District Court for the Northern District of California, seeks to recover losses for investors who purchased Alto stock between February 2, 2024, and October 22, 2024 [1].

The complaint alleges that the Offering Documents and the company's public statements contained untrue statements of material fact or omitted necessary information, making them misleading. Specifically, it is claimed that ALTO-100, the company's lead product, was less effective in treating major depressive disorder (MDD) than represented, leading to overstated clinical, regulatory, and commercial prospects [2].

On October 22, 2024, Alto released topline results from a Phase 2b trial of ALTO-100, revealing that it did not meet its primary endpoint. This announcement led to a significant drop in the company's stock price, falling from $16.00 to $4.36 per share [1].

Investors who suffered losses during the relevant time frame are encouraged to contact Faruqi & Faruqi LLP for further information. The firm is investigating potential claims against Alto Neuroscience, Inc. regarding its IPO and subsequent stock performance. Investors can reach Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) [3].

References

[1] Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO. PR Newswire. Retrieved from https://www.morningstar.com/news/pr-newswire/20250822dc55992/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-alto-neuroscience-inc-and-certain-officers-anro
[2] Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANRO. PR Newswire. Retrieved from https://www.morningstar.com/news/pr-newswire/20250822ny56801/levi-korsinsky-reminds-shareholders-of-a-lead-plaintiff-deadline-of-september-19-2025-in-alto-neuroscience-inc-lawsuit-anro
[3] Rosen Law Firm Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ANRO. Globe Newswire. Retrieved from https://www.morningstar.com/news/globe-newswire/9516523/rosen-a-longstanding-law-firm-encourages-alto-neuroscience-inc-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-anro